8-K: Nektar Therapeutics Implements 1-for-15 Reverse Stock Split and Increases Authorized Shares

Nektar Therapeutics has announced a 1-for-15 reverse stock split to take effect on June 8, 2025, alongside an increase in authorized common shares from 300 million to 390 million, both approved by stockholders.

Summary

• Nektar Therapeutics filed a Certificate of Amendment to its Certificate of Incorporation on June 6, 2025, to increase the number of authorized shares of common stock from 300,000,000 to 390,000,000 shares.
• This increase in authorized shares was approved by the company's stockholders at the Annual Meeting held on May 23, 2025, and became effective upon filing on June 6, 2025.
• The company also filed a Certificate of Amendment on June 6, 2025, to effect a one-for-fifteen (1:15) reverse stock split of its common stock.
• The reverse stock split will become effective at 11:59 p.m. Eastern Time on June 8, 2025.
• Following the reverse stock split, every fifteen shares of common stock issued and outstanding will be automatically combined into one share.
• No fractional shares will be issued; instead, fractional shares will be rounded up for shares held directly with The Depository Trust Company, or rounded down to the nearest whole share for awards under the 2017 Amended and Restated Performance Incentive Plan.
• Trading of Nektar's common stock on a split-adjusted basis will commence at market open on June 9, 2025, under the existing symbol NKTR and a new CUSIP number (640268306).
• The reverse stock split will not alter the total number of authorized common shares, which will remain at 390,000,000 after the authorized shares amendment.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the increase in authorized shares offers future flexibility, the primary action of a reverse stock split is generally viewed as a defensive measure to address a low stock price, often signaling underlying challenges rather than strong positive momentum. It does not fundamentally improve the company's operations or financial health.

Positives

• The increase in authorized common shares to 390,000,000 provides Nektar Therapeutics with greater flexibility for future equity financing, strategic partnerships, or other corporate purposes.
• The reverse stock split is intended to increase the per-share trading price of the common stock, which can help the company meet minimum bid price requirements of the Nasdaq Capital Market and potentially improve the stock's marketability and appeal to a broader investor base.

Negatives

• A reverse stock split is often perceived negatively by the market as it typically signals a company's struggle with a low stock price and can be a reactive measure to avoid delisting from an exchange.
• While the reverse split increases the per-share price, it does not change the company's underlying market capitalization or fundamental value, and there is no guarantee it will lead to sustained price improvement or increased investor confidence.

Future Outlook

The company's common stock will begin trading on a split-adjusted basis under its existing symbol NKTR and a new CUSIP number starting at market open on June 9, 2025.

Management Comments

• Mark A. Wilson, Chief Legal Officer and Secretary, signed the filing on behalf of Nektar Therapeutics.

Industry Context

Reverse stock splits are a common corporate action, particularly for biotechnology companies or those with volatile stock prices, often undertaken to increase the per-share price to meet exchange listing requirements (e.g., Nasdaq's minimum bid price) or to make the stock more attractive to institutional investors who may have policies against investing in low-priced stocks. The increase in authorized shares is also a common move to provide flexibility for future capital needs or strategic transactions, which is typical in capital-intensive industries like biotech.

Corporate Governance

Stakeholder Impact

• Shareholders will own fewer shares of common stock, but each share will have a proportionally higher price. The total value of their holdings immediately after the split should remain the same, assuming no market reaction.
• The reverse split may improve the stock's marketability and perception, potentially attracting a broader range of investors, including institutional investors who may avoid low-priced stocks.
• The increase in authorized shares provides the company with more capacity for future equity issuance, which could lead to dilution for existing shareholders if new shares are issued without corresponding value creation.

Next Steps

• Commencement of split-adjusted trading of common stock on Nasdaq under the existing symbol NKTR and new CUSIP number on June 9, 2025.

Key Dates

Recommendation

Keywords

Nektar Therapeutics, Reverse Stock Split, Authorized Shares, Common Stock, Corporate Governance, SEC Filing, 8-K, Nasdaq